By vgreene, 10 July, 2019 If adenocarcinoma/large cell/NSCLC not otherwise specified AND advanced/metastatic dz, then consider, at minimum:
By vgreene, 10 July, 2019 EGFR mutation testing (category 1): NCCN recommends EFGR (exon 19 deletions, p.L858R point mutation in exon 21 assoc w/ responsiveness to EGFR TKI tx);1 but ASCO strongly recommends against evaluating EFGR by immunohistochemistry for selection of pts for
By vgreene, 10 July, 2019 For all NSCL CA pts: Strongly consider broad molecular profiling to identify rare drive mutations for which effective drugs may already be available, to better counsel pts re clinical trial availability1 or for any non-small cell histology where clinical